Spots Global Cancer Trial Database for The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Official Title: The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Study ID: NCT05802407
Interventions
Study Description
Brief Summary: The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, , China
Contact Details
Name: Chunmei Bai, MD
Affiliation: Peking Union Medical College Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
